Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · IEX Real-Time Price · USD
1.140
+0.060 (5.56%)
May 17, 2024, 4:00 PM EDT - Market closed
Company Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies.
The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.
It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies.
The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Xilio Therapeutics, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Oct 22, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Dr. Rene Russo BCPS, Pharm.D. |
Contact Details
Address: 828 Winter Street Waltham, Massachusetts 02451 United States | |
| Phone | 617-833-1027 |
| Website | xiliotx.com |
Stock Details
| Ticker Symbol | XLO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001840233 |
| CUSIP Number | 98422T100 |
| ISIN Number | US98422T1007 |
| Employer ID | 85-1623397 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rene Russo BCPS, Pharm.D. | President, Chief Executive Officer and Director |
| Kevin M. Brennan | Senior Vice President of Finance and Accounting |
| Christopher Frankenfield | Chief Operating Officer |
| Dr. Uli Bialucha Ph.D. | Chief Scientific Officer |
| Julissa Viana | Vice President of Corporate Communications |
| Stacey J. Davis | Chief Business Officer |
| Dr. Katarina Luptakova M.D. | Chief Medical Officer |
| Dr. Scott Coleman Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| May 6, 2024 | EFFECT | Notice of Effectiveness |
| Apr 30, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2024 | 424B5 | Filing |
| Apr 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |